RRM1、BRCA-1表达与ⅢBⅣ期肺鳞癌患者GP方案-南京医科大学.docVIP

RRM1、BRCA1表达与ⅢB/Ⅳ期肺鳞癌患者GP方案化疗疗效的相关性研究 万一元 程劲松 惠红霞 王晓炜 吴健 【摘要】 目的 观察肿瘤组织核糖核酸调节亚单位1（RRM1）、乳腺癌易感基因1（BRCA1）表达ⅢB/Ⅳ期ⅢB/Ⅳ期肺鳞癌、PS）评分02分预计生存期≥3个月的患者入选本研究P方案化疗，每3周重复，BRCA1表达高低分为组、BRCA1表达）组BRCA1阳性表达组BRCA1阴性表达组BRCA1阳性表达。BRCA1表达阳性率分别为47.4%（37/78）、51.3%（40/78），RRM1、BRCA1不同表达的患者临床特征比较差异无统计学意义。（2）78例患者A组组组组。BRCA1可作为GP方案疗效的预测分子；仅RRM1、BRCA1低表达的肺鳞癌患者，可能是GP化疗方案的优势人群。 【关键词】 核糖核酸调节亚单位1；乳腺癌易感基因1； 癌，肺鳞癌； 抗肿瘤联合化疗方案； 治疗结果 ------------------- 作者单位：223300 南京医科大学附属淮安第一医院肿瘤内科（万一元、程劲松、惠红霞、王晓炜），病理科（吴健） 通信作者：万一元，Email：wanyiyuan-wyy@ The correlation between chemotherapeutic efficacy and ribonucleotide reductase subunit l and breast cancer susceptibility gene 1 protein expression in the squaomas lung cancer patients WAN Yi-yuan*, Cheng Jin-song, HUI Hong-xia, WANG Xiao-wei, WU Jian.*Department of Medical Oncology, No1 Hospital of Huai’an City Affiliated Nanjing Medical College, Jiangsu Province, Huaian 223300, China Corresponding author: WAN Yi-yuan, E-mail:wanyiyuan-wyy@ [Abstract] Objective This trial was designed to determine whether ribonucleotide reductase subunit l (RRM1) and breast cancer susceptibility gene1 (BRCA1)protein expression in tumor tissue could predict the efficacy of stage ⅢB/Ⅳsquaomas lung cancer patients treated with gemcitabine combined cisplatin (GP) chemotherapy regiments. Methods A total of 89 stage ⅢB/Ⅳsquaomas lung cancer patients were included, only 78 patients were evaluated. Bronchoscopy or lung puncture tumor biopsies samples were obtained and RRM1, BRCA1 protein expression were examined immunohistochemically before chemotherapy, then the patients were randomly assigned to received 4 to 6 cycles of GP chemotherapy regiments. Follow-up was done afterwards until the patient died or could not be informed. Response rate (RR), overall survival (OS) and time to tumor progression (TTP) were assessed. Result Among 78 evaluated patients, the positive expression rate of RRM1, BRCA1 was 47.4%( 37/78) and 51.3 %( 40/78), respectively. There was no significant dif